ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for samfunnsmedisin
  • Artikler, rapporter og annet (samfunnsmedisin)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for samfunnsmedisin
  • Artikler, rapporter og annet (samfunnsmedisin)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study

Permanent link
https://hdl.handle.net/10037/16333
DOI
https://doi.org/10.1002/ijc.31266
Thumbnail
View/Open
article.pdf (781.4Kb)
Accepted manuscript version (PDF)
Date
2018-01-19
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Busund, Marit Katinka; Stensland-Bugge, Nora; Braaten, Tonje; Waaseth, Marit; Rylander, Charlotta; Lund, Eiliv
Abstract
Receptor-defined subtypes of breast cancer represent distinct cancer types and have differences in risk factors. Whether the two main hormonal forms of oral contraceptives (OCs); i.e. progestin-only (POC) and combined oral contraceptives (COC), are differentially associated with these subtypes are not well known. The aim of our study was to assess the effect of POC and COC use on hormone receptor-defined breast cancer risk in premenopausal women in a prospective population-based cohort – The Norwegian Women and Cancer Study (NOWAC). Information on OC use was collected from 74,862 premenopausal women at baseline. Updated information was applied when follow-up information became available. Multiple imputation was performed to handle missing data, and multivariable Cox regression models were used to calculate hazard ratios (HR) for breast cancer. 1,245 incident invasive breast cancer cases occurred. POC use ≥5 years was associated with ER+ (HR = 1.59, 95% CI 1.09– 2.32, ptrend = 0.03) and ER+/PR+ cancer (HR = 1.63, 95% CI 1.07–2.48, ptrend = 0.05), and was not associated with ER− (pheterogeneity = 0.36) or ER−/PR− (pheterogeneity = 0.49) cancer. COC use was associated with ER− and ER−/PR− cancer, but did not increase risk of ER+ and ER+/PR+ cancer. Current COC use gave different estimates for ER/PR‐defined subtypes (pheterogeneity = 0.04). This is the first study to show significant associations between POC use and hormone receptor-positive breast cancer. The lack of power to distinguish effects of POC use on subtype development calls for the need of larger studies to confirm our finding.
Description
This is the peer reviewed version of the following article: Busund, M., Bugge, N.S., Braaten, T., Waaseth, M., Rylander, C. & Lund, E. (2018). Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study. International Journal of Cancer, 142(11), 2293-2302, which has been published in final form at https://doi.org/10.1002/ijc.31266. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Publisher
Wiley
Citation
Busund, M., Bugge, N.S., Braaten, T., Waaseth, M., Rylander, C. & Lund, E. (2018). Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study. International Journal of Cancer, 142(11), 2293-2302. https://doi.org/10.1002/ijc.31266
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (samfunnsmedisin) [1516]

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)